Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis.

Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ.

Semin Arthritis Rheum. 2013 Aug;43(1):9-17. doi: 10.1016/j.semarthrit.2012.11.007. Epub 2013 Jan 2. Review.

PMID:
23290690
2.

Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis.

Crnkic Kapetanovic M, Saxne T, Jönsson G, Truedsson L, Geborek P.

Arthritis Res Ther. 2013 Oct 30;15(5):R171. doi: 10.1186/ar4358.

3.

Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.

Das S, Vital EM, Horton S, Bryer D, El-Sherbiny Y, Rawstron AC, Ponchel F, Emery P, Buch MH.

Ann Rheum Dis. 2014 May;73(5):909-12. doi: 10.1136/annrheumdis-2013-204417. Epub 2014 Jan 2.

PMID:
24385201
4.

Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis.

Schoels M, Aletaha D, Smolen JS, Wong JB.

Ann Rheum Dis. 2012 Aug;71(8):1303-8. doi: 10.1136/annrheumdis-2011-200490. Epub 2012 Jan 30. Review.

PMID:
22294630
5.

Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital.

Couderc M, Mathieu S, Pereira B, Glace B, Soubrier M.

Arthritis Care Res (Hoboken). 2013 Apr;65(4):648-52. doi: 10.1002/acr.21865.

6.

Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.

Leffers HC, Ostergaard M, Glintborg B, Krogh NS, Foged H, Tarp U, Lorenzen T, Hansen A, Hansen MS, Jacobsen MS, Dreyer L, Hetland ML; all departments of rheumatology in Denmark.

Ann Rheum Dis. 2011 Jul;70(7):1216-22. doi: 10.1136/ard.2010.140129. Epub 2011 May 8.

PMID:
21551512
7.

Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: systematic review and meta-analysis of observational studies.

Salgado E, Maneiro JR, Carmona L, Gómez-Reino J.

Joint Bone Spine. 2014 Jan;81(1):41-50. doi: 10.1016/j.jbspin.2013.04.004. Epub 2013 Jun 2. Review.

PMID:
23731644
8.

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF.

Ann Rheum Dis. 2011 Sep;70(9):1575-80. doi: 10.1136/ard.2010.148759. Epub 2011 May 12.

PMID:
21571731
9.

Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs.

Narvaez J, Díaz-Torné C, Ruiz JM, Hernandez MV, Torrente-Segarra V, Ros S, Rodriguez de la Serna A, Díaz-López C, Sanmartí R, Nolla JM.

Clin Exp Rheumatol. 2011 Nov-Dec;29(6):991-7. Epub 2011 Dec 22.

PMID:
22133052
10.

Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.

Navarro-Millán I, Singh JA, Curtis JR.

Clin Ther. 2012 Apr;34(4):788-802.e3. doi: 10.1016/j.clinthera.2012.02.014. Epub 2012 Mar 22. Review.

11.

Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums.

Navarro G, Taroumian S, Barroso N, Duan L, Furst D.

Semin Arthritis Rheum. 2014 Feb;43(4):458-69. doi: 10.1016/j.semarthrit.2013.08.001. Epub 2013 Nov 18.

PMID:
24262929
12.

[Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis].

Wollenhaupt J, Krüger K.

Z Rheumatol. 2010 Sep;69(7):618-25. doi: 10.1007/s00393-009-0532-5. German.

PMID:
20703488
13.

Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure.

Solau-Gervais E, Prudhomme C, Philippe P, Duhamel A, Dupont-Créteur C, Legrand JL, Houvenagel E, Flipo RM.

Joint Bone Spine. 2012 May;79(3):281-4. doi: 10.1016/j.jbspin.2011.05.002. Epub 2011 Jul 2.

PMID:
21724444
14.

[Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis].

Quartuccio L, Salvin S, Saracco M, Lombardi S, Fabris M, Mansutti E, Maset M, Pellerito S, De Vita S.

Reumatismo. 2009 Jul-Sep;61(3):182-6. Italian.

15.

Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.

Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM; British Society for Rheumatology Biologics Register.

J Rheumatol. 2012 Feb;39(2):240-6. doi: 10.3899/jrheum.110610. Epub 2011 Dec 15.

16.

Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.

Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, Cimmino M, Morassi P, Masolini P, Pellerito R, Cutolo M, Puttini PS, De Vita S.

Rheumatology (Oxford). 2009 Dec;48(12):1557-9. doi: 10.1093/rheumatology/kep314. Epub 2009 Sep 29.

17.

Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.

Lal P, Su Z, Holweg CT, Silverman GJ, Schwartzman S, Kelman A, Read S, Spaniolo G, Monroe JG, Behrens TW, Townsend MJ.

Arthritis Rheum. 2011 Dec;63(12):3681-91. doi: 10.1002/art.30596.

18.

Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.

Isaacs JD.

Expert Opin Biol Ther. 2009 Dec;9(12):1463-75. doi: 10.1517/14712590903379494. Review.

PMID:
19916731
20.

Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.

Daïen CI, Morel J.

Mediators Inflamm. 2014;2014:386148. doi: 10.1155/2014/386148. Epub 2014 Jan 12. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk